Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Patient Preferences Regarding Anticoagulation Therapy in Patients with Cancer Having a VTE Event - a Discrete Choice Experiment in the Cosimo Study

Nils Picker, MSc, Alexander T Cohen, MBBS, MSc, MD, Anthony Maraveyas, MD PhD, Jan Beyer-Westendorf, MD, Agnes Yuet Ying Lee, MD MSc, FRCPC, Lorenzo G Mantovani, Yoriko De Sanctis, MS, Khaled Abdelgawwad, Samuel Fatoba, Miriam Bach, Thomas Wilke, Prof. Dr. rer. oec.

Blood (2019) 134 (Supplement_1): 2159.

https://doi.org/10.1182/blood-2019-128095

Published: 2019

Journal Articles

Baseline Characteristics and Clinical Outcomes from the Cancer Associated Thrombosis - Patient Reported Outcomes with Rivaroxaban (COSIMO) Trial

Anthony Maraveyas, MD PhD, Jan Beyer-Westendorf, MD, Agnes Yuet Ying Lee, MD MSc, FRCPC, Lorenzo G Mantovani, Yoriko De Sanctis, MS, Khaled Abdelgawwad, Samuel Fatoba, Miriam Bach, Alexander T Cohen, MBBS, MSc, MD

Blood (2019) 134 (Supplement_1): 2161.

https://doi.org/10.1182/blood-2019-126810

Published: 2019

Journal Articles

Rivaroxaban and Extended Thromboprophylaxis in Acutely Ill Medical Patients with History of Cancer: Insights from the Magellan and Mariner Studies

Alex C. Spyropoulos, MD, Concetta Lipardi, MD PhD, Alexander T Cohen, MBBS, MSc, MD, Biljana Vučković, MD PhD, Jianfeng Xu, PhD, Wentao Lu, PhD, Theodore E. Spiro, MD, Elliot S. Barnathan, MD, Gary E. Raskob, PhD

Blood (2019) 134 (Supplement_1): 3671.

https://doi.org/10.1182/blood-2019-122945

Published: 2019

Journal Articles

Association of Bleeding Severity with Mortality with in-Hospital and Extended Thromboprophylaxis in the Medically Ill in the Magellan Trial

Alex C. Spyropoulos, MD, Gary E. Raskob, PhD, Alexander T Cohen, MBBS, MSc, MD, Walter Ageno, Jeffrey I. Weitz, MD, Theodore E. Spiro, MD, Wentao Lu, PhD, Concetta Lipardi, MD PhD, Elliot S. Barnathan, MD

Blood (2019) 134 (Supplement_1): 2441.

https://doi.org/10.1182/blood-2019-122930

Published: 2019

Journal Articles

Increased Risk of Death in Acutely Ill Medical Patients with Asymptomatic Proximal Deep Vein Thrombosis or Symptomatic Venous Thromboembolism: Insights from the Magellan Study

Gary E. Raskob, PhD, Alex C. Spyropoulos, MD, Alexander T Cohen, MBBS, MSc, MD, Jeffrey I. Weitz, MD, Walter Ageno, Yoriko De Sanctis, MS, Wentao Lu, PhD, Jianfeng Xu, PhD, John Albanese, BS, MBA, Chiara Sugarmann, BSN, MSHS, Concetta Lipardi, MD PhD, Theodore E. Spiro, MD, Elliot S. Barnathan, MD

Blood (2019) 134 (Supplement_1): 163.

https://doi.org/10.1182/blood-2019-122934

Published: 2019

Journal Articles

Safety and Effectiveness of Apixaban, LMWH, and Warfarin Among Venous Thromboembolism Patients with Active Cancer: A Retrospective Analysis Using Four US Claims Databases

Alexander T Cohen, MBBS, MSc, MD, Allison Keshishian, Theodore Lee, MD, Gail Wygant, RN, MS, Lisa Rosenblatt, MD MPH, Patrick Hlavacek, MPH, Jack Mardekian, PhD, Daniel Wiederkehr, MPH, Janvi Sah, MS, Xuemei Luo, PhD

Blood (2019) 134 (Supplement_1): 326.

https://doi.org/10.1182/blood-2019-121769

Published: 2019

Journal Articles

Safety and Effectiveness of Apixaban, LMWH and Warfarin Among Venous Thromboembolism (VTE) Patients with Active Cancer: A Subgroup Analysis of VTE Risk Scale

Blood (2019) 134 (Supplement_1): 327.

https://doi.org/10.1182/blood-2019-126931

Published: 2019

Journal Articles

Clinical Impact and Course of Anticoagulant-Related Major Bleeding in Cancer Patients

Noémie Kraaijpoel, MSc, Nick van Es, MD, Suzanne M Bleker, MD, Marjolein P Brekelmans, MD, Elise S Eerenberg, MD, Saskia Middeldorp, MD PhD Professor of MDcine, Alexander T Cohen, MBBS MSc MD, Harry R Büller, MD PhD

Blood (2016) 128 (22): 2611.

https://doi.org/10.1182/blood.V128.22.2611.2611

Published: 2016

Journal Articles

The Safety and Efficacy of Full Versus Reduced Dose Betrixaban in the Acute Medically Ill VTE (Venous Thromboembolism) Prevention with Extended Duration Betrixaban (APEX) Trial

Alexander T Cohen, MBBS MSc MD, Rim Halaby, MD, Serge Korjian, MD, Yazan Daaboul, MD, Donald Szlosek, Douglas Arbetter, MPH, Samuel Z. Goldhaber, MD, Russell Hull, MBBS, Adrian Hernandez, MD, Alexander Gold, MD, Brian Wiens, PhD, Robert Harrington, MD, C. Michael Gibson, MD

Blood (2016) 128 (22): 3824.

https://doi.org/10.1182/blood.V128.22.3824.3824

Published: 2016

Journal Articles

Predictors of Major Bleeding in Patients with First Venous Thromboembolism Treated with Vitamin K Antagonists in Clinical Practice in the United Kingdom

Alexander T Cohen, MBBS MSc MD, Christopher Wallenhorst, MSc, Anja Katholing, MSc, Melissa Hamilton, MPH, Sreevalsa Unniachan, MBBS MPH, Carlos Martinez, MDMSc

Blood (2015) 126 (23): 2327.

https://doi.org/10.1182/blood.V126.23.2327.2327

Published: 2015

Journal Articles

An Adaptive-Design Dose-Ranging Study of PD 0348292, a New Oral Factor Xa Inhibitor, for Thromboprophylaxis after Total Knee Replacement Surgery.

Alexander T Cohen, MBBS, MSc, MD, FRACP, Donald Armstrong, BSc., MD, FRCSC, Tadeusz Gazdzik, MD, Camilla Ryge, MD, PhD, Raphael Pak, PhD, Jaap Mandema, PhD, Rebecca Boyd, PhD, Scott McBride, MA, Lorenzo A. DiCarlo, MD

Blood (2008) 112 (11): 980.

https://doi.org/10.1182/blood.V112.11.980.980

Published: 2008

Journal Articles

Venous Thromboembolism Risk and Prophylaxis Practices in Surgical Patients with Active Cancer: Findings from the Global ENDORSE Survey.

Ajay K Kakkar, PhD, Alexander T Cohen, MBBS, MSc, MD, FRACP, Victor F Tapson, MD, Jean-Francois Bergmann, MD, Samuel Z. Goldhaber, MD, Frederick A Anderson, Jr., PhD

Blood (2008) 112 (11): 984.

https://doi.org/10.1182/blood.V112.11.984.984

Published: 2008

Journal Articles

The Unmet Need for Extended Thromboprophylaxis in Acutely Ill Medical Patients: The Findings of IMPROVE, ENDORSE and EXCLAIM.

Frederick A Anderson, Jr., PhD, Russell D Hull, MBBS, Sebastian M Schellong, MD, Bruno Deslandes, Victor F Tapson, MD, Meyer Michel Samama, MD, PharmD, Alexander GG Turpie, MD, Roger D Yusen, MD, MPH, Herve Decousus, MD, Alexander T Cohen, MBBS, MSc, MD, FRACP, Manuel Monreal, MD

Blood (2008) 112 (11): 1981.

https://doi.org/10.1182/blood.V112.11.1981.1981

Published: 2008

Journal Articles

Impact of Surgery Type and Co-Morbidities on Venous Thromboembolism prophylaxis Practices in Patients Undergoing Major Surgical Procedures in Acute Care Hospitals Worldwide: A Subanalysis of Data from the ENDORSE Survey

Ajay K Kakkar, PhD, Alexander T Cohen, MBBS, MSc, MD, FRACP, Victor F Tapson, MD, Jean-Francois Bergmann, MD, Samuel Z. Goldhaber, MD, Frederick A Anderson, Jr., PhD

Blood (2008) 112 (11): 171.

https://doi.org/10.1182/blood.V112.11.171.171

Published: 2008

NARROW

Patient Preferences Regarding Anticoagulation Therapy in Patients with Cancer Having a VTE Event - a Discrete Choice Experiment in the Cosimo Study

Baseline Characteristics and Clinical Outcomes from the Cancer Associated Thrombosis - Patient Reported Outcomes with Rivaroxaban (COSIMO) Trial

Rivaroxaban and Extended Thromboprophylaxis in Acutely Ill Medical Patients with History of Cancer: Insights from the Magellan and Mariner Studies

Association of Bleeding Severity with Mortality with in-Hospital and Extended Thromboprophylaxis in the Medically Ill in the Magellan Trial

Increased Risk of Death in Acutely Ill Medical Patients with Asymptomatic Proximal Deep Vein Thrombosis or Symptomatic Venous Thromboembolism: Insights from the Magellan Study

Safety and Effectiveness of Apixaban, LMWH, and Warfarin Among Venous Thromboembolism Patients with Active Cancer: A Retrospective Analysis Using Four US Claims Databases

Safety and Effectiveness of Apixaban, LMWH and Warfarin Among Venous Thromboembolism (VTE) Patients with Active Cancer: A Subgroup Analysis of VTE Risk Scale

Clinical Impact and Course of Anticoagulant-Related Major Bleeding in Cancer Patients

The Safety and Efficacy of Full Versus Reduced Dose Betrixaban in the Acute Medically Ill VTE (Venous Thromboembolism) Prevention with Extended Duration Betrixaban (APEX) Trial

Predictors of Major Bleeding in Patients with First Venous Thromboembolism Treated with Vitamin K Antagonists in Clinical Practice in the United Kingdom

An Adaptive-Design Dose-Ranging Study of PD 0348292, a New Oral Factor Xa Inhibitor, for Thromboprophylaxis after Total Knee Replacement Surgery.

Venous Thromboembolism Risk and Prophylaxis Practices in Surgical Patients with Active Cancer: Findings from the Global ENDORSE Survey.

The Unmet Need for Extended Thromboprophylaxis in Acutely Ill Medical Patients: The Findings of IMPROVE, ENDORSE and EXCLAIM.

Impact of Surgery Type and Co-Morbidities on Venous Thromboembolism prophylaxis Practices in Patients Undergoing Major Surgical Procedures in Acute Care Hospitals Worldwide: A Subanalysis of Data from the ENDORSE Survey

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only